LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day
28.10.2020 08:05:00 CET | LEO Pharma | Press release
BALLERUP, Denmark, October 28, 2020 - LEO Pharma A/S today marked World Psoriasis Day by launching a series of videos featuring patients that outline the everyday challenges of living with psoriasis.
The #everydaypsoriasis videos give personal perspectives on the challenges of living with psoriasis. To accompany the patient videos, LEO Pharma staff from around the world filmed a manifesto during COVID home-working restrictions, outlining their everyday commitment to supporting patients with psoriasis:
WATCH OUR MANIFESTO VIDEO HERE
The #everydaypsoriasis campaign video. More information can be found at www.everydaypsoriasis.com
The LEO Pharma campaign is in support of the annual International Federation of Psoriasis Associations (IFPA) World Psoriasis Day. This annual awareness day is dedicated to people living with psoriasis or psoriatic arthritis and is aimed at spreading information and raising the profile of these debilitating diseases.
October 2020 marks the second year of a three-year ‘Connected, Informed, United’ IFPAtheme, with the theme of ‘Be Informed’ the focus of this year.
Henrik Kyndlev, Director of Global External Communications at LEO Pharma, said: “We’re proud to support IFPA’s important initiative, and are keen to do our part in helping people ‘Be Informed’ about psoriasis this year.”
“Our campaign supports this theme in a very simple but powerful way - namely by bringing attention to some everyday psoriasis stories of real-life patients. After all, psoriasis is not just about a single day, but is an everyday challenge for many patients.”
The #everydaypsoriasis campaign centres around three audio-interviews with psoriasis patients, whose stories are brought to life with short animations depicting the everyday challenges they face.
‘Jane’ talks about how the simple, everyday experience of grocery shopping is a challenge, as she feels people are looking at her skin, and think her psoriasis is contagious. Psoriasis is in fact an auto-immune disease and so is not contagious – one of the key messages IFPA want to focus on in 2020.
Watch Jane’s video: click here
‘Steve’ speaks about the sense of futility he sometimes feels because of the cycle of psoriasis flares, and the feeling of going through a “revolving door”.
Watch Steve’s video: click here
‘Becky’ talks about how having psoriasis as a child affected her confidence, and the ongoing challenge she feels now as a young adult.
Watch Becky’s video: click here
Alexandre Fevre, Vice President of Global Marketing, Psoriasis, at LEO Pharma, said of the campaign, “For many patients, psoriasis goes beyond just being a cosmetic challenge. Nearly 60 percent1 of people with psoriasis say their disease is a large problem in their everyday life.”
“This campaign draws attention to some of the everyday psoriasis challenges and gives a voice to psoriasis patients. We also hope it demonstrates LEO Pharma’s continued commitment to helping people achieve healthy skin.”
“As we say on our campaign website, the encouraging news for many patients is that there are ways to manage the condition. Not just treatments, but lifestyle changes too. If you or someone you know is experiencing #everydaypsoriasis challenges, consider approaching your doctor for advice.”
The #everydaypsoriasis videos can be viewed at www.everydaypsoriasis.com.
About psoriasis
Psoriasis is a chronic, systemic inflammatory disease that primarily affects the skin in 125 million people worldwide.1,2 About 80% of patients are affected by plaque psoriasis, the most common clinical form of psoriasis.2 The symptoms of plaque psoriasis are itchy or painful, scaly, inflamed plaques. Plaques may appear anywhere on the body, but often appear on the scalp, knees, elbows and torso.3 Psoriasis is characterized as mild when less than 3% of the body is affected and moderate to severe when more than 3% of the body is affected.4
References
1. Stern RS, et al. J Investig Dermatol Symp Proc. 2004;9(2):136-9.
2. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659.
3. Menter A et al. J Am Acad Dermatol 2008;58:826.
4. Armstrong AW et al. JAMA Dermatol. 2013;149(10):1180–1185.
To view this video from www.youtube.com, please give your consent at the top of this page.Our Manifesto Video
Contacts
Henrik Kyndlev
HDTDK@leo-pharma.com
+45 3140 6180
About LEO Pharma
The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i Danmark7.5.2026 09:00:00 CEST | Pressemeddelelse
LOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline5.5.2026 09:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 5 May, 2026 – In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while significantly increasing commercial investments to support the global roll-out of Anzupgo® and the addition of Spevigo® to the portfolio. LEO Pharma also made significant strategic progress and advanced innovation through the acquisition of Replay’s next-generation gene therapy platform targeting rare genetic skin diseases, the approval of Enstilar® in China and the continued late-stage development activities for Anzupgo®, including FDA acceptance for review in adolescents with chronic hand eczema. Financial highlights LEO Pharma’s revenue increased by 4% to DKK 3,521 million, and by 9% at constant exchange rates (CER). The revenue growth was led by North America (30% at CER) and Rest of World (13% at CER), whereas sales in Europe declined by 1% at CER. Revenue from the dermatology portfolio grew by 11% (CER), driven by the strat
LEO Pharma bolsters rare skin disease focus through acquisition of Replay gene therapy platform30.4.2026 15:00:00 CEST | Pressemeddelelse
Acquisition adds high-payload herpes simplex virus (HSV) gene therapy targeting genetic skin diseases to LEO Pharma’s pipeline and further expands the company’s presence in rare dermatology Combines LEO Pharma’s six decades of dermatology expertise with Replay’s next-generation gene therapy platform to advance innovation for patients with rare skin diseases The lead program targets dystrophic epidermolysis bullosa (DEB), a devastating genetic skin disease with significant unmet medical need.
LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar®17.4.2026 09:00:00 CEST | Pressemeddelelse
NMPA approval of Enstilar® in China marks a significant milestone for LEO Pharma, expanding access to a new treatment option for the estimated 6.5 million adults living with plaque psoriasis in the world’s largest market measured by patient numbers.1 China represents a strategically important pillar in LEO Pharma’s long-term growth, and the approval strengthens the company’s position in medical dermatology by expanding its psoriasis portfolio in an exciting market for innovative treatments. Enstilar builds on LEO Pharma’s established leadership in topical psoriasis treatments, offering a clinically proven, foam-based formulation that has been widely adopted in more than 50 markets worldwide and is supported by robust phase 3 clinical data.2,3
LEO Pharma announces FDA Acceptance of supplemental NDA for ANZUPGO® (delgocitinib) cream for the treatment of Chronic Hand Eczema in children aged 12-1715.4.2026 14:00:00 CEST | Pressemeddelelse
The application is supported by positive data from the pivotal Phase 3 DELTA TEEN trial in the primary and key secondary endpoints.1 If approved, ANZUPGO will be the first treatment option specifically indicated for pediatric patients aged 12–17 living with moderate to severe chronic hand eczema (CHE).
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom